Caliper Completes Divestiture of Product Lines to Biotage | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences has completed the sales of its RapidTrace solid phase extraction and TurboVap evaporation product lines to Biotage for $16.5 million in cash.

The divestiture, announced a couple of weeks ago, also includes Biotage assuming liabilities of about $500,000 associated with the products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.